I have got a great new stock coming up but I want to look at IDGJ.
* IDGJ Up almost Twelve Percent TODAY
* LLSR Up over Twenty-six Percent TODAY
* MEDP – Up over Thirty-three Percent TODAY
* LXES – Up over Fourteen Percent TODAY
* PWBI – Up over Twelve Percent TODAY
* IDGJ continues to execute in the anticounterfeiting and loss prevention area.
I am impressed by the ongoing press releases from IDGJ and the focus today on the pharmaceutical counterfeiting provides unlimited potential for IDGJ. This opportunity allows them to grow their revenue while keeping their cost base in check.
IDGJ has continuously announced that it can ramp up to one hundred million units if required.
I thought that today’s ten announced trademark-enforced pharmaceutical label produced by the collaboration of IDGLOBAL and ATL have potential within the pharmaceutical industry that cannot be understated in terms of day to day revenue.
The aggressive tradeshow and conference schedule the two companies are jointly attending to showcase these ten product deliverables over the next five months have the potential to deliver staggering numbers within the pharmaceutical business.
IDGLOBAL and ATL Pharma Security Label Systems™ signed a ten year contract for IDGLOBAL to supply its Nano-Molecular Marking™ anti-counterfeiting technology to ATL Pharma Security Label Systems™ as announced on July 24, 2007 and December 4, 2007.
I asked our Research Department to check out the latest news on drug counterfeits. I was completely shocked by the data they turned up. There is no question but that tracking conterfeits is crucial to our world.
The United Nations is focusing on this issue and issued a report just this month.
The United Nations Report states outright that counterfeit drugs are killing people from China to Canada and they “promote the development of new strains of viruses, parasites and bacteria … for example in the case of malaria or HIV.” And in many countries their manufacture and distribution is not even illegal.
The United Nations Inter-regional Crime and Justice Research Institute (Unicri) said this month that “the Asian and African regions seem to be the most affected by counterfeit medicines” and ” more than 30 per cent of medicines on sale could be counterfeits in parts of Asia and parts of Latin America while in the former Soviet republics counterfeit medicines could constitute more than 20 per cent of market value.”
I was shocked to read the real consequence of countefeited drugs. This was more serious than I understood. The growing global industry of fake and pseudo-pharmaceuticals has already defeated some legitimate cures: the time-tested malaria treatment chloroquine now fails most of the time in Africa because wrong doses in counterfeits have helped the parasite to evolve.
A recent study in the Journal of Tropical Medicine and International Health estimated that 86 per cent of under-strength fakes analysed in Kenya and Congo came from India and China. Unsurprisingly, this “may be because of the laxity of Indian and Chinese regulatory bodies in checking exported medicines,” it said.
Sometimes the entire firm is operating to low standards and at other times rogue employees work after hours to increase production and sell the drugs to criminal networks.
There can be no question but that the opportunity that IDGJ has to penetrate the pharmaceutical market is staggering!
